Alembic gets final USFDA approval for Venetoclax; first-to-file status may bring 180 days of exclusivity
The generic of AbbVie's Venclexta has an estimated $1,584 million US market (IQVIA, year to June 2026). Alembic was a first ANDA applicant — approval No. 228 is not routine.
₹798.65
Oct 30, 2026
MID-CAP
by market cap ≈ ₹15,698.5 Cr
$1,584 million
IQVIA, 12 months ending June 2026
180 days
may be eligible — first ANDA applicant
228
plus 20 tentative; 248 cumulative
−20.0%
adjusted high ₹998 (Nov 4, 2025)
A first-to-file approval on a $1,584 million drug
USFDA grants final approval for Venetoclax Tablets, 10 mg, 50 mg and 100 mg
Alembic announced final approval from the US Food & Drug Administration for its Abbreviated New Drug Application (ANDA) for Venetoclax Tablets, 10 mg, 50 mg and 100 mg — therapeutically equivalent to AbbVie's Venclexta. The tablets are indicated for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and, in combination with azacitidine, decitabine or low-dose cytarabine, for newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older or with comorbidities that preclude intensive induction chemotherapy. Per IQVIA, the product had an estimated US market of $1,584 million in the twelve months ending June 2026. The filing reached the exchange at 18:29 IST on Friday, October 30 — after market close, so the stock has not yet traded on this news within this report's price data.
Read:This is Alembic's 228th final ANDA approval, but the filing itself separates it from the other 227: Alembic states it was a first ANDA applicant with a paragraph IV certification and may be eligible for 180 days of generic drug exclusivity. A defined window on a drug of this size is a bounded, identifiable revenue opportunity rather than one more unit in the approval count.
BSE filing — press release, Oct 30, 2026The exact words of the press release matter. Alembic says it "was a first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification" and that it "may be eligible for 180 days of generic drug exclusivity." The filing states eligibility as a possibility, not a confirmed grant — and the indefinite article leaves open whether Alembic shares first-applicant status with others. Nothing in the announcement states a launch date, a pricing plan, or whether other generic versions are approved.
What can be said from the filing alone: the reference product's US market was estimated at $1,584 million for the twelve months ending June 2026, and Alembic now holds a final — not tentative — approval with a potential exclusivity claim attached. How much of that market Alembic can capture, at what price erosion, and over what period, are all outside what the company has disclosed. Investors should treat the $1,584 million figure as the size of the pool, not as Alembic's opportunity.
Third US approval announced in October
Final approval for Valganciclovir for Oral Solution, 50 mg/mL
Alembic announced USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. The press release was filed at 15:29 IST, at the end of Tuesday's session.
BSE filing — press release, Oct 27, 2026Final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%
Alembic announced USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%. Filed on a Saturday evening; the first tradable session was Monday, October 19.
BSE filing — press release, Oct 17, 2026The regulatory backdrop at the plant level is also clean on the facilities the company has filed about recently. On September 11 Alembic reported that an unannounced USFDA bioequivalence inspection at its Vadodara facility, conducted August 31 to September 10, 2026, closed with no Form 483 observations; on September 16 it reported that the USFDA issued an Establishment Inspection Report and closed the inspection carried out at the same Vadodara bioequivalence facility in March 2025. Neither filing concerns a manufacturing site for any specific product, but both are the compliance signals the agency's approval cadence rests on.
How the stock traded into the approval
The stock came into this announcement from a soft October: from a late-September close of ₹863.75 (Sep 25) it drifted to ₹764.90 on October 23, then recovered over five sessions to ₹798.65 by Friday, October 30 — up +4.4% from that low, but still −20.0% below the 52-week adjusted high of ₹998 set on November 4, 2025. The Venetoclax filing reached the exchange at 18:29 IST on Friday after that close, so none of the price action above reflects it; the first traded session after the announcement will be the market's actual verdict.
Revenue up 25.7% year-on-year in the June quarter
The most recent reported quarter, Q1 FY27 (June 2026), had consolidated revenue of ₹2,149.77 crore — up 25.7% over Q1 FY26's ₹1,710.72 crore — with net profit of ₹172.36 crore (+12.2% year-on-year) and an operating margin of 15.44%. The Q4 FY26 net profit of ₹201.54 crore is not a clean comparison: it included a tax credit of ₹82.91 crore and an exceptional charge of ₹24.76 crore, with pre-tax profit at just ₹117.52 crore. The next test of the run-rate comes quickly — the board meets on November 4, 2026 to approve results for the quarter and half-year ended September 30.
Q4 FY26 net profit exceeds pre-tax profit because of a tax credit of ₹82.91 Cr; the quarter also carried an exceptional charge of ₹24.76 Cr.
The next data points
First traded session
The Venetoclax filing landed after Friday's close. The first session after it is the market's first chance to price the approval.
Nov 4 results
Board meeting on November 4, 2026 for Q2 and H1 FY27 results — and any management commentary on Venetoclax launch timing. The trading window has been closed since October 1 and reopens 48 hours after the results.
Exclusivity confirmation
The filing says Alembic may be eligible for 180 days of generic drug exclusivity. A launch announcement, or disclosure confirming sole or shared first-applicant status, would convert the possibility into a measurable opportunity.
Approval cadence
Three US approvals were announced in October alone (Venetoclax, Valganciclovir, the ciprofloxacin-dexamethasone otic suspension), on a base of 228 final ANDA approvals. Whether the US pipeline keeps delivering at this rate is the medium-term story.
The approval itself is a verifiable fact; its value is not yet one. Alembic holds a final USFDA approval on a product whose US reference market was $1,584 million over the twelve months to June 2026, with a potential — not confirmed — 180-day exclusivity attached. The company has disclosed no launch date, no confirmed exclusivity status, and no revenue expectation, and none should be assumed on its behalf.
The stock enters the event at ₹798.65, 20% below its 52-week high, with the market's reaction still untraded and results four days away. The November 4 board meeting and any subsequent launch disclosure are the points at which this announcement either converts into numbers or remains one more line — albeit an unusually large one — in the approval count.
Informational and educational content only. Not investment advice.